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More and more implantable cardioverter-deﬁbrillators (ICDs) are implanted as primary prevention of sudden cardiac death
(SCD). However, major problem in practice is to identify high-risk patients for SCD. Diﬀerent methods for noninvasive risk
stratiﬁcation do not have a suﬃcient positive or negative predictive value. Since current approaches lead to implantation of
ICDs in a large number of patients who will never suﬀer an arrhythmic event and simultaneously patients still die of SCD who
currently did not seem eligible for primary preventive ICD implantation, there is a need for additional tools for risk stratiﬁcation.
Epidemiological studies point to a hereditary risk of SCD. Diﬀerent susceptibility of each person concerning arrhythmogenic
events might be explained by genetic polymorphisms. By obtaining an individual “pattern” of polymorphisms of genes encoding
for proteins which are important in arrhythmogenesis in one patient, risk stratiﬁcation in primary prevention of SCD might by
improved.
1.Introduction
Sudden cardiac death (SCD) is one of the most frequent
causes of death [1]. Since 1980, implantable cardioverter-
deﬁbrillators (ICDs) are available as an eﬀective, continu-
ously improved therapy option [2]. Within the last thirty
years, initially sole secondary preventive indications for im-
plantation of an ICD have been expanded: more and more
ICDs are implanted as primary prevention of SCD [3]. How-
ever, major problem in clinical practice is to identify high-
risk patients for SCD. Since—on the one hand—evidence
actually available [3] leads to implantation of ICDs in a large
numberofpatientswhowillneversuﬀeranarrhythmic event
and—on the other hand—patients still die of SCD who did
not seem eligible for ICD implantation, there is a profound
need for additional tools for risk stratiﬁcation.
2.EpidemiologyofSuddenCardiacDeath
Epidemiologic studies report of more than 300000 SCDs/
annumintheUnitedStates[1].SCDisdeﬁnedasunexpected
death of cardiac cause within one hour after onset of any
symptoms [4]. SCD occurs in newborn to 6-month old
children (“sudden infant death syndrome”), and incidence
of the disease peaks again in 45-to-75-year olds [1, 5].
In one third of all patients with coronary heart disease
(CHD), SCD is the ﬁrst clinical manifestation of the
disease. 80% of all SCDs are caused by CHD, 20% by car-
diomyopathies (dilated or hypertrophic) and, respectively,
electrical diseases of the heart (long QT, short QT, Brugada-
syndrome). 75% of patients with SCD are male [1].
Contrary to common assumptions, acute myocardial
infarction can be found in only 20%ofall patientswith SCD.
However, SCD is mostly caused by an electrical instability of
ventricular myocardium which in turn is often generated by
chronic ventricular ischemia [6].
Compared to normal population, risk of SCD is in-
creased 2–4 times in patients with a high risk for CHD, 4–
6 times in patients with apparent CHD and rises up to 6–
9 if these patients develop congestive heart failure (CHF)
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3.Pathophysiologyof SuddenCardiacDeath
Electrical instability of ventricular myocardium and con-
secutive arrhythmias leading to SCD is a result of complex
interactions between triggering events and an arrhythmo-
genic substrate (often diseased myocardium) [7]. In most
patients with SCD, ventricular ﬁbrillation degenerated from
precedent ventricular tachycardia can be found as terminal
arrhythmia [8].
Lethal arrhythmia can be triggered by acute myocardial
ischemia. Ventricular scar caused by previous myocardial
infarction can either act as a trigger without manifest
ischemia [7, 9] or as a substrate due to isolated regions of
myocytes with slow conduction properties (e.g., endocardial
cells which survived myocardial infarction due to nutrition
and oxygenation from intracavitary blood) therefore predis-
posingre-entrycircuitsforsustainedventriculartachycardias
[7].
Besides focal autonomy and triggered activity due to aft-
erdepolarisations, re-entry is considered as the main mech-
anism for ventricular tachycardia in patients with CHD
[10, 11].
SCD due to bradycardia, asystole, or pulseless electrical
activity can be found more often in patients with severe
structural heart disease [12].
4.TherapyofSuddenCardiacDeath
In the 1980s, antiarrhythmics were used in patients (mainly
after myocardial infarction) with high-risk for SCD in order
topreventmaligntachycardias.However,thesedrugsshowed
a considerable, sometimes fatal proarrhythmic potential
in several large randomized studies [13]. Antiarrhythmics
including amiodarone which is regarded as most eﬀective
and accordingly safe [14–16] are also inferior compared to
today’s standard treatment of SCD, the implantable car-
dioverter/deﬁbrillator (ICD [2]). Thus, sole (i.e., without
concomitant implantation of an ICD) primary preventive
antiarrhythmic therapyinordertoanticipateSCDisobsolete
[3].
On the one hand, incidence of malign tachycardias
within an observation period is also high in patients cur-
rently considered as high-risk suﬀering SCD, but—on the
otherhand—these patientsrepresent onlya small percentage
ofall cases ofSCD.Inthemajority ofpatientswith SCD,only
little or even no clinical signs for a potential occurrence of
lethal arrhythmias can be observed [17].
Besidesreliableandaccordinglyfeasiblemethodstoiden-
tify high risk patients for SCD, this discrepancy depicts the
main problem of primary prevention of SCD with ICDs.
5.CurrentProblemsinPrimary
PreventiveICD Therapy
Current primary prevention of SCD (implantation of an
ICD) is mostly limited to patients with considered high-
risk for SCD. According to present level of knowledge, this
high risk collective is mainly deﬁned by having reduced left
ventricular ejection fraction (LV-EF) and/or clinical symp-
toms of CHF. Primary preventive implantation of an ICD
can be considered in all patients with severely reduced LV-
EF (<35%) and little or moderate symptoms (NYHA II-III)
or even independent of symptomatology for patients with
ischemic cardiomyopathy [3].
However, problems are implicated by using reduced LV-
EF to identify candidates for ICD implantation: ﬁrst, after
myocardial infarction, most cases of SCD can be found in
patients with better preserved LV-EF [18–20]. Second, only a
minority of patients received an ICD due to severely reduced
LV-EF de facto suﬀer from life-threatening arrhythmias [16,
21, 22]. Finally, at as far as 50% of all patients with CHF,
cause of death is progressive heart failure but not malign
ventricular arrhythmias [23].
Aswell as antiarrhythmics, ICDsare alsonotfree of risks:
proportion of infectious complications, inadequate shock
deliveries, and other device malfunctions is considerable
[24–26]. Despite proven eﬃciency of primary prevention of
SCD [14, 16, 21], ICD implantation is still expensive and
depicts a signiﬁcant burden of health care system [27].
A multiplicity of invasive and, respectively, non-invasive
methods in order to better select patients for primary pre-
ventive ICD implantation was developed. Some approaches
are based on signal-averaged ECGs [28], QT variability,
heart rate variability, T-wave variability, microvolt T-wave
alternans, heart rate turbulence, deceleration capacity, or
the so-called Wedensky modulation index [29]. Holter-ECG
can be also used to evaluate the incidence of nonsustained
ventricular tachycardias [30]a sw e l la si n v a s i v ee l e c t r o -
physiological analyses (programmed ventricular stimulation
[30]).Ventriculararrhythmogenicsubstratecanbedescribed
using cardiac magnetic resonance imaging [31]. Finally,
some laboratory parameters like BNP[32]o rC R P[ 33] seem
to predict the risk for SCD in some patients.
All these approaches—neither alone nor combined [19]
—donothaveanadequatepositiveorrathernegative predic-
tive value. Thus, LV-EF and symptoms of CHF (NYHA clas-
siﬁcation) are still mainly used to legitimate primary preven-
tive ICD implantation with the most additional denotations
of the above-mentioned methods [3, 34].
In summary, delineated problems of current primary
preventive ICD therapy underline the need for new methods
for a better risk stratiﬁcation of primary prevention of SCD.
6.Genetic Predispositionfor
SuddenCardiacDeath
In comparison with normal population, ﬁrst-degree relatives
of patients with SCD have an increased risk for this purpose
(relative risk 1.5–2.7) [35–37].
Family history concerning SCD is more often positive in
patients with ventricular ﬁbrillation up to the time of ﬁrst
myocardial infarction (odds ratio 2.7) [38].
Positive family history potentiates the individual risk in
patients suﬀering from certain diseases predisposing for
SCD, as for example, ﬁvefold in patient with hypertrophic
cardiomyopathy [39].ISRN Cardiology 3
Taken together, these data speak for a familiar accumu-
lation of SCD, maybe because of common genes inﬂuencing
individualvulnerabilitytolife-threateningarrhythmias inde-
pendent of a familiar predisposition for ischemic heart dis-
ease in general.
Inaddition,dependenceofriskonthenumberofaﬀected
family members (the more, the higher) is compatible with
a complex genetic architecture where predisposing alleles
increase the risk for SCD in case of arrhythmogenic environ-
ment variables in an additive or synergistic way [40, 41].
7.GeneticPolymorphismsasa Risk
StratiﬁcationTool inPrimaryPreventive
ICDTherapy
Geneticvariations (so calledpolymorphisms) are the basisof
human uniqueness. Speciﬁc pros and cons concerning state
of health or susceptibility to certain diseases would not be
expected from variations of genes coding, for example, for
the physiognomy of a single person. However, occurrence
of variations of genes coding for proteins essentially for
physiological functions (e.g., cellular calcium homoeostasis
or function of ion channels) might be disadvantageous in
terms of, for example, proarrhythmic compensatory mecha-
nisms duringmyocardial ischemia, disbalanceofelectrolytes,
or also after drug intake. Therefore, polymorphisms of
these genes might explain diﬀerent susceptibility of persons
concerning arrhythmogenic events and may suit for non-
invasive risk stratiﬁcation of SCD: if, for example, two
patients are considered to have the same risk for SCD using
currently available approaches for risk stratiﬁcation but then
in only one patient SCDactually occurs, this diﬀerential out-
come might be explained by genetic polymorphisms.
Asaclinicalaim, identiﬁcationofseveralpolymorphisms
ina patientwhich mightplayarolein arrhythmogenesis may
result in an individual genetic “polymorphism pattern” in
order to characterize the individual risk for occurrence of
arrhythmic events. Besides the well-established parameters
(LV-EF,NYHA class), this “geneticpattern” might thenact as
another helpful tool in decision-making concerning primary
preventive ICD implantation.
Associations of many polymorphisms—most notably
of genes coding for ion channels—and SCD were already
reported [42].
Besides cardiac ion channels, molecular signaling cas-
cades like, for example, the beta-1-receptor cascade and ac-
cordingly the renin-angiotensin-aldosterone-system (RAAS)
play an important role concerning regulation of cardiac elec-
trophysiology.
On the one hand, many polymorphisms of these signal-
ing cascades with unclear function importance are known;
on the other hand there are others with relevance demon-
strated in vitro and others associated with the incidence of
arrhythmias in patients with CHF.
For example, sensitivity of theb e t a - 1 - r e c e p t o ri nv i t r o
[43] and heart rate [44]a n ds u r v i v a l[ 45] in a small cohort
of patientswith CHF is inﬂuenced by the Ser49Gly polymor-
phism (frequency ofoccurrence in normal population22%).
Intransfectedﬁbroblasts,theArg389Glypolymorphism(fre-
quency of occurrence in normal population 30%) causes a
threefold increase of the activity of the adenylate cyclase
[46] and seems to enhance the incidence of arrhythmias in
patients with CHF [47].
Development of an arrhythmic cardiac ﬁbrosis is essen-
tially inﬂuenced by the RAAS [48]. It has been shown that
patients with CHF rather die of a progressive heart failure
than of a malign arrhythmia if a common polymorphism of
angiotensin can be detected [49]. Further RAAS polymor-
phisms were identiﬁed but not yet validated in patients with
CHF.
Intracellular calcium overload is a well-known cause of
triggered ventricular arrhythmias as a result of delayed after-
depolarisations [10]. Polymorphisms of proteins important
for regulation of intracellular calcium homoeostasis were
also described (e.g., Glu692Val (frequency of occurrence
in normal population 5%) of the Na+/Ca2+ exchanger,
Gln2958Arg (frequency of occurrence in normal population
20–30%) of the cardiac ryanodine type 2 receptor). As
cellular calcium homoeostasis is per se defective in patients
with CHF, it can be speculated that these polymorphisms
causeanincreasedriskforoccurrenceofmaligntachycardias.
8.Conclusion
Asasummary,utilizationofthegeneticinformationfornon-
invasive risk stratiﬁcation of SCD seems to be feasible. By
obtainingan individual“pattern”ofpolymorphisms ofgenes
encoding for proteins which are important in arrhythmoge-
nesis in one patient, risk stratiﬁcation in primary prevention
ofSCDmightbyimproved,andcurrentproblemsinprimary
preventive ICD therapy might be minimized.
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